Pharmacists have a role in managing anticoagulant therapy in acutely ill hospitalized patients at risk for VTE, including protocol development and research, identifying unmet need and the value of prophylaxis in medically ill patients, and implementing practical DVT and PE prevention strategies. Consensus guidelines (e.g., COVID-19 ISTH 2020, COVID-19 ACC) have provided some guidance for COVID-19 infection and the connection to deep vein thrombosis and pulmonary embolism.
SPEAKERS
John Fanikos, R.Ph., M.B.A., is Chief of Pharmacy Services at Brigham and Women's Hospital (BWH) in Boston, Massachusetts. Mr. Fanikos is responsible for the overall Pharmacy Department operations. As part of his research interests, he has worked closely with the BWH Thromboembolism Research Group for over 25 years. He has authored and co-authored over 100 peer reviewed articles and textbook chapters on medication use with a specific emphasis on optimizing medication utilization. His research focus has been identifying and avoiding the problems and pitfalls of medication use.
Relevant Financial Relationship Disclosure with an Ineligible Company*
- Consultant, Pfizer
- Consultant, Pacira
- Consultant, Boehringer-Ingelheim
- Consultant, Allergan
- Consultant, Alexion
All of the relevant financial relationships have been mitigated.
*As defined by the Standards of Integrity and Independence definition of ineligible company.
Allison E. Burnett, Pharm.D., PhC, CACP, is Antithrombosis Stewardship Pharmacist at the University of New Mexico (UNM) Hospital in Albuquerque, New Mexico. Dr. Burnett serves as coordinator of the Inpatient Antithrombosis Stewardship program at the UNM Health Sciences Center and as an associate clinical professor at the UNM College of Pharmacy.
Dr. Burnett received her pharmacy doctorate from the UNM College of Pharmacy and completed a pharmacy practice residency at Boston Medical Center in Boston, Massachusetts.
Dr. Burnett serves on the National Certification Board for Anticoagulation Providers and has the distinct honor of being the president of the Anticoagulation Forum, a national nonprofit organization whose mission is education and empowerment of patients and clinicians towards optimized use of anticoagulant therapies.
Relevant Financial Relationship Disclosure
No relevant financial relationship with an ineligible company.*
*As defined by the Standards of Integrity and Independence definition of ineligible company.
All others in control of the content of this activity do not have a relevant financial relationship (RFR) with an ineligible company.
This podcast is provided by ASHP and sponsored by Janssen Pharmaceuticals, Inc.
